explore -WSS

explore

author：knowledge 2025-09-29 20:51:04 - browse：4

Pfizer is this year’s anti-Eli Lilly. If David Ricks is the best biopharma CEO of 2023, then Pfizer CEO Albert Bourlais, unfortunately, the worst.

My annual Worst Biopharma CEO list is typically populated with blockheads and scoundrels. That’s not why Bourla is here. The reason is accountability. Strategic missteps, financial miscalculations, and scientific setbacks have plunged Pfizer into a deep crisis. Bourla is the man at the top, so the responsibility lies with him.

Pfizer shares have fallen 50% this year to their lowest level in more than a decade, erasing nearly $140 billion in market value. In 2022, the company delivered $100 billion in revenue, boosted by a widely used Covid vaccine and Covid treatment. This year, Covid product sales evaporated — and will fall further next year — leaving a vacuum Pfizer is struggling to fill with aging medicines nearing the end of their patent lives, and newer drugs and vaccines that have not performed as expected.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Driven by the pandemic, applicants flood public health schools

leisure time

WSS

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Vir antibody drug aimed at influenza A fails in clinical trial

Latigo launches with $135 million for Vertex

Abbott's new heart device gets FDA advisory panel nod

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

hotspot

explore

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Why Congress must ban federal programs from using QALYs

Heart attack and stroke risk calculators need revising

Congress considering partial increase for doctor pay in Medicare

Dobbs anniversary: the lost opportunity of abortion as health care

Too many hospitalized Covid

Psychedelics group wrestles with new pharma identity

Latigo launches with $135 million for Vertex

FDA approval of Sarepta Duchenne genetic therapy gives me hope

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

entertainment

Winning ticket for $1 billion Powerball jackpot sold in California

Resistance to opioid

Tocagen's brain cancer gene therapy trial continues. Investors worry

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

EF3 tornado rips through North Carolina amid extreme weather nationwide

Latigo launches with $135 million for Vertex

leisure time

leisure time

entertainment

explore